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Abstract—An efficient and economical method was developed for the synthesis of 3-substituted indoles by one pot three-component 
coupling reaction of a substituted or unsubstituted benzaldehyde, N-methylaniline, and indole or N-methylindole using Yb(OTf)3-SiO2 as 
a catalyst. All the synthesized compounds were evaluated for inhibition of cell proliferation of human colon carcinoma (HT-29), human 
ovarian adenocarcinoma (SK-OV-3), and c-Src kinase activity. The 4-methylphenyl (4o and 4p) and 4-methoxyphenyl (4q) indole 
derivatives inhibited the cell proliferation of SK-OV-3 and HT-29 cells by 70−77% at a concentration of 50 µM. The unsubstituted 
phenyl (4d) and 3-nitrophenyl (4l) derivatives showed the inhibition of c-Src kinase with IC50 values of 50.6 µM and 58.3 µM, 
respectively.  
The 3-substituted indoles are structural units of 
many natural and biologically interesting compounds, 
which possess various pharmacological activities.1−4 
The indole derivatives serve as a scaffold in a number 
of antibacterial,5 antiviral,6 and protein kinase 
inhibitors.7 Indole-based derivatives have been 
investigated for anticancer activities. Indole-3-carbinols 
have been previously reported to exhibit anticancer 
activities against a number of human cancers through 
acting on different cellular signaling pathways.8 1-
Aroylindoles and 3-aroylindoles have shown potent 
cytotoxicity against different human cancer cell lines.9  
Several indole derivatives have shown tyrosine 
kinase inhibition in low micromolar range.7,10 3-
Substituted 2,2′-dithiobis(1H-indoles) have been 
reported to show inhibition against protein tyrosine 
kinases (PTKs), such as EGFR and non receptor v-Src 
tyrosine kinases.11 SU5416 (Fig. 1) is an indole-based 
FIK-1/KDR inhibitor, and is currently in clinical trials 
against ovarian cancer.12−14  
The Src family of tyrosine kinases (SFKs) is 
comprised of nine tyrosine kinases viz., Src, Lck, Fyn, 
Yes, Hck, Blk, Fgr, Lyn, and Yrk. SFKs have critical 
roles in multiple signaling pathways that control a 
diverse spectrum of biological activities, such as growth 
factor signaling, cell growth, division, differentiation, 
survival, adhesion, migration, and invasion.16 c-Src 
tyrosine kinase is the prototype of SFKs. c-Src 
upregulation has been observed in a number of 
epithelial tumors, such as ovary, colon, lung, breast, 
prostate, and pancreas when compared with the normal 
tissues. c-Src serves as a key modulator of cancer cell 
invasion and metastasis through reducing cell adhesion 
and facilitating motility.17−19 Thus, considerable interest 
has been evolved around the design of Src kinase 
inhibitors for the treatment of cancer and anti-invasion 
therapy.20 A number of small molecule inhibitors21−22 
have shown potential biological activity as both anti-
proliferative and anti-invasive agents in preclinical 
studies in different solid tumor types.23−26  
 
Figure 1. Chemical structure of SU5416. 
In continuation of our efforts towards the 
development of organic transformations catalyzed by 
metal triflates27 and synthesis of small molecules as 
anticancer agents and/or c-Src kinase inhibitors,15,28 
herein we report an expeditious one-pot synthesis of 3-
substituted indoles by three component condensation 
catalyzed by Yb(OTf)3−SiO2 (Scheme 1) and evaluation 
of their anticancer and c-Src kinase inhibitory activity.  
Scheme 1. Synthesis of 3-substituted indoles. 
The 3-indole derivatives were synthesized by one 
pot condensation reaction of indole or N-methylindole, 
a substituted or unsubstituted benzaldehyde, and N-
methylaniline. The reaction condition optimizations 
were performed by monitoring a model reaction 
between indole, 4-chlorobenzaldehyde and N-
 methylaniline. The model reaction was carried out in 
various solvents, such as DCM, DMSO, DMF, THF, 
acetonitrile, and ionic liquid [bmim][BF4], using 
Yb(OTf)3−SiO2 as a catalyst. Among these solvents 
acetonitrile was found to be most efficient reaction 
media to give 4a in good yield (88%) while the reaction 
yield in other solvents was very poor.  
Furthermore, catalyst conditions were optimized by 
using different variations of catalyst, catalyst loading, 
and time period of reaction (Table 1). The yield of 4a 
was poor and required longer time when reaction was 
performed with either Yb(OTf)3 or silica gel alone. 
Among the screened catalysts Yb(OTf)3−SiO2 (5−10 
mol %), Ce(OTf)3−SiO2 (5 mol %), and Cu(OTf)2−SiO2 
(5 mol %) were found to give good yield of 4a. The 
Yb(OTf)3−SiO2 (5 mol %) gave the highest yield (88%) 
of 4a and, therefore, further studies were carried out 
using this as a catalyst of choice. In case of other acidic 
catalysts supported on silica gel such as pTSA−SiO2 
(71%), FeCl3−SiO2 (59%) the yield of 4a was moderate 
but accompanied with generation of 
bis(indolyl)methane (5−30%) as a side product. 
Table 1. Optimization of reaction condition for model reaction 
generating 4a. 
 
Catalyst Catalyst  
(mol %) 
Time (h) Yield (%)a 
SiO2 - 6 15 
Yb(OTf)3 5 4 72 
Zn(OTf)2 5 4 52 
Ce(OTf)3 5 4 71 
Cu(OTf)2 5 4 68 
Ba(OTf)2 5 4 50 
Yb(OTf)3-SiO2 1 2 47 
Yb(OTf)3-SiO2 2 2 58 
Yb(OTf)3-SiO2 3 2 67 
Yb(OTf)3-SiO2 4 2 74 
Yb(OTf)3-SiO2 5  2 88 
Yb(OTf)3-SiO2 10 2 84 
Zn(OTf)2-SiO2 5 2 62 
Ce(OTf)3-SiO2 5 2 81 
Cu(OTf)2-SiO2 5 2 81 
Ba(OTf)2-SiO2 5 2 67 
FeCl3-SiO2 5 2 59 
pTSA-SiO2 5 3 71 
aIsolated yield. 
The standardized reaction conditions were used 
further for the synthesis of different 3-substituted indole 
derivatives.29 Indole or N-methylindole, N-
methylaniline, and a substituted or unsubstituted 
benzaldehyde were reacted to obtain 3-substituted 
indole derivatives (4a−r). The products and their yields 
are summarized in Table 2. All the compounds were 
characterized by 1H NMR, 13C NMR, and mass 
spectroscopy. The reaction is assumed to proceed 
through formation of imine through reaction of the 
benzaldehyde and N-methylaniline followed by 
nucleophilic attack of indole to give 3-substituted 
indoles as shown in Scheme 2. The structure of product 
is consistent with the synthesis of 3-substituted indoles 
via multicomponent condensation reaction of indoles, 
aldehyde, and amines.30 
 Scheme 2. Plausible mechanism for synthesis of 4. 
Table 2. Synthesis of different 3-substituted indoles (4a-r) and 
their Src kinase inhibitory activity.  
 
Product R R' R'' Yield 
(%)a 
IC50 
(µM)b 
4a H H 4-Cl 88 >150 
4b H H 4-CH3 83 >150 
4c H H 4-CH3O 86 >150 
4d H H H 78 50.6 
4e H H 4-OH 75 >150 
4f H H 3-Br, 4-OH 84 >150a 
4g H H 3-CH3O 82 >150 
4h H H 2,4-CH3O 81 >150 
4i H CH3 H 79 >150 
4j H CH3 4-Cl 81 98.3 
4k H CH3 4-CH3 82 60.5 
4l H H 3-NO2 51 58.3 
4m 5-Br H H 72 71.6 
4n 5-OCH3 H 4-OCH3 88 100.0 
4o 5-OCH3 H 4-CH3 85 >150 
4p 5-Br H 4-CH3 78 >150 
4q 5-Br H 4-OCH3 80 106 
4r 5-OCH3 H 4-Cl 83 87 
aIsolated yield; bThe concentration at which 50% of enzyme 
activity is inhibited. 
An array of 18 diversely substituted indoles was 
evaluated against Src kinase. The results of Src kinase 
inhibitory activity of compounds (4a−r) are shown in 
Table 2. Among all the screened compounds, 4d, 4j, 4k, 
4l, and 4r showed modest inhibition of Src kinase with 
 IC50 values of 50.6−98.3 µM. The data suggest that the 
presence of either electron donating or electron 
withdrawing groups on the phenyl ring (R′′ position) 
was mostly less tolerated as shown in compounds 4a−c, 
4e−i, and 4n−p with IC50 value of ≥100 µM. The 
unsubstituted indole derivative 4d showed an IC50 value 
of 50.6 µM while introduction of electron withdrawing 
group -NO2 at 3-position of phenyl ring (4l) exhibited 
comparable inhibitory activity (IC50 = 58.3 µM).  
DS visualizer docking studies31 were used to study 
the interactions of 4d with the ATP binding site of the 
Src kinase. Compound 4d was superimposed on a 
reference anilinoquanzoline AZD05030, a dual specific 
c-Src/Abl kinase inhibitor32 in complex with the Src 
kinase (PDB 2H8H). 
 
 
Figure 2: Comparison of interactions of 4d (grey) and 
AZD05030 (oxygens (red), nitrogens (purple), carbons 
(light green), chlorine (green)) in ATP binding site of 
the Src kinase based on molecular modeling. The 
compounds and side chains of amino acids (yellow) are 
rendered in stick styles. Compounds are in the lowest 
energy conformers predicted. The Figure is drawn using 
the Accelrys DS visualizer 2.5 system. 
As can be seen from Figure 2, 4d interacts with the 
ATP binding pocket in slightly different orientation 
when compared with reference quinazoline ligand. The 
chloro group in reference ligand oriented towards and 
interacts with Ala403, whereas in 4d phenyl rings lie in 
hydrophobic binding pocket. N1−H of indole ring in 
compound 4d shows specific hydrogen bonding 
interaction with Ile336. The hydrogen bonding 
interaction was not observed when N1 was methylated 
in 4i. This interaction may have contributed to higher 
inhibitory activity of unmethylated compounds 4d (IC50 
= 50.6 µM) versus N1-methylated analog 4i (IC50 > 150 
µM). On the other hand, N1-methylated compounds 4j 
and 4k exhibited improved inhibition activity versus 4a 
and 4b, respectively (Table 2), suggesting that 
hydrophobic interactions of methyl with Ile336 may 
also contribute to modest inhibitory activity. The 
binding energy for 4d was observed as –7.42 kcal/mol 
and estimated inhibition constant at 3.67 µM while the 
reference ligand binding energy and estimated 
inhibition constant were –7.36 kcal/mol and 4.01 µM, 
respectively. The RMSD from reference ligand is 1.230 
Ǻ.  
The effect of the compounds on the cell 
proliferation of human ovarian adenocarcinoma (SK-
OV-3) and colon adenocarcinoma (HT-29) cancer cells 
that also overexpress c-Src,33,34 was also evaluated at 
the concentration of 50 µM (Fig. 3). In general, most of 
the compounds were more active against SK-OV-3 cells 
than HT-29 cells. Indole-based SU5416 is also currently 
in clinical trials against ovarian cancer. Consistently 
compounds 4o−r inhibited the cell proliferation of both 
cancer cells significantly while 4a only inhibited SK-
OV-3. The 4-methylphenyl (4o and 4p) and 4-
methoxyphenyl (4q) indole derivatives inhibited the cell 
proliferation of SK-OV-3 and HT-29 cells by 70−77% 
whereas 4-cholorderivatives 4a and 4r inhibited the 
growth of ovarian cancer cells (SK-OV-3) by 
approximately 72% and 77%, respectively (Fig. 3). 
Structure−activity relationship studies suggest that the 
presence of bromo- or methoxy-substituent at position 5 
of indole ring (R) in addition to methyl, methoxy, or 
chloro substitutent at as R′′ is critical for maximum 
anticancer activity as seen in compounds 4o−r. In 
general, poor correlation was observed between Src 
kinase inhibitory potency of the compounds and the 
inhibition of cell proliferation in cancer cells, 
suggesting that differential cellular uptake and 
contribution of other mechanisms in anticancer 
activities of these compounds. Compounds 4d and 4r 
that showed modest Src kinase inhibition, also inhibited 
the growth of SK-OV-3 by 55% and 77%, respectively. 
In conclusion, we have developed an ecofriendly 
and economical method for the synthesis of 3-
substituted indoles by one pot three-component 
coupling reaction of a benzaldehyde, N-methylaniline, 
and indole or N-methylindole using Yb(OTf)3−SiO2 as 
catalyst. To the best of our knowledge, this is the first 
report of the synthesis and evaluation of 3-substituted 
indole derivatives as Src kinase inhibitors and 
anticancer agents. The compounds 4d, 4j, 4k, 4l, and 4r 
showed modest inhibition of Src kinase while 
compounds 4o−r inhibited the cell proliferation of 
ovarian and colon cancer cells significantly. 
Structure−activity relationship studies revealed the 
importance of the presence of a substituent at position 5 
of indole ring (R) for anticancer activity. This study 
provides insights for further optimizing of substituted 
indoles for the discovery of the Src kinase inhibitors 
and/or anticancer agents. 
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Figure 3. Inhibition of HT-29 and SK-OV-3 cell proliferation by compounds 4a−r (50 µM) after 72 h incubation. The results are shown as the percentage 
of the control DMSO that has no compound (set at 100%). All the experiments were performed in triplicate.
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